Dolors Colomer

Grupo de investigación

Terapias experimentales en neoplasias linfoides Group leader (R4)

dcolomer@clinic.cat 0000-0001-7486-8484

Síguelo/a en:

El perfil Researchgate de Dolors . Este enlace se abre en una nueva pestaña.

Publicaciones destacadas

Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery

Autores:
Playa-Albinyana, Heribert; Arenas, Fabian; Colomer, Dolors;

Referencia: Expert Opinion On Drug Discovery 2021.
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

Autores:
Valero, Juan Garcia; Matas-Cespedes, Alba; Arenas, Fabian; Rodriguez, Vanina; Carreras, Joaquim;

(...)

Cid, Maria C; Campo, Elias; Lopez-Guillermo, Armando; Colomer, Dolors; Perez-Galan, Patricia.

Referencia: Leukemia 2021.
Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets

Autores:
Lopez-Oreja, Irene; Playa-Albinyana, Heribert; Arenas, Fabian; Lopez-Guerra, Monica; Colomer, Dolors;

Referencia: Cancers 2021.
Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

Autores:
Gimenez, Neus; Tripathi, Rupal; Giro, Ariadna; Rosich, Laia; Lopez-Guerra, Monica;

(...)

Perez-Galan, Patricia; Delgado, Julio; Campo, Elias; Farres, Judith; Colomer, Dolors.

Referencia: Scientific Reports 2020.
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells

Autores:
Lopez-Guerra, Monica; Xargay-Torrent, Silvia; Fuentes, Patricia; Roldan, Jocabed; Gonzalez-Farre, Blanca;

(...)

Lopez-Guillermo, Armando; Puente, Xose S; Campo, Elias; Toribio, Maria L; Colomer, Dolors.

Referencia: Oncogene 2020.
Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia

Autores:
Gimenez, Neus; Schulz, Ralph; Higashi, Morihiro; Aymerich, Marta; Villamor, Neus;

(...)

Lopez-Guerra, Monica; Campo, Elias; Rosich, Laia; Seiffert, Martina; Colomer, Dolors.

Referencia: Leukemia 2020.
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy

Autores:
Silkenstedt, Elisabeth; Arenas, Fabian; Colom-Sanmarti, Berta; Xargay-Torrent, Silvia; Higashi, Morihiro;

(...)

Bea, Silvia; Toribio, Maria L; Campo, Elias; Lopez-Guerra, Monica; Colomer, Dolors.

Referencia: Journal Of Experimental & Clinical Cancer Research 2019.
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia

Autores:
Lee-Verges, Eriong; Hanna, Bola S; Yazdanparast, Haniyeh; Rodriguez, Vanina; Leonor Rodriguez, Marta;

(...)

Perez-Galan, Patricia; Lopez-Guerra, Monica; Campo, Elias; Seiffert, Martina; Colomer, Dolors.

Referencia: International Journal Of Cancer 2019.
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+T-cells that undergo functional exhaustion in secondary lymphoid tissues

Autores:
Hanna, Bola S; Roessner, Philipp M; Yazdanparast, Haniyeh; Colomer, Dolors; Campo, Elias;

(...)

Stilgenbauer, Stephan; Schmidt, Manfred; Gabriel, Richard; Lichter, Peter; Seiffert, Martina.

Referencia: Leukemia 2019.
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

Autores:
Gimenez, Neus; Martinez-Trillos, Alejandra; Montraveta, Arnau; Lopez-Guerra, Monica; Rosich, Laia;

(...)

Lopez-Otin, Carlos; Lopez-Guillermo, Armando; Campo, Elias; Colomer, Dolors; Villamor, Neus.

Referencia: Haematologica 2019.

Proyectos destacados

Transpyrenean network of advanced therapies in non-Hodgkin lymphoma - THERAVLINFO (INTERREG-POCTEFA program EFA123/1)

Investigador/a principal: Dolors Colomer Pujol, Patricia Pérez Galán

Duración: 01/01/2024

Web: http://theravlinfo.eu/
Nuevos modelos para el estudio de las alteraciones genéticas recurrentes y resistencia a fármacos en la leucemia linfática crónica

Investigador/a principal: Dolors Colomer Pujol

Financiador: MINECO

Código: RTI2018-094584-B-I00

Duración: 01/08/2019 - 31/12/2021
Cross border network of personalized immunotherapies in non-Hodgkin lymphoma.

Investigador/a principal: Patricia Pérez Galán

Financiador: EU-INTERRREG-POCTEFA (Programa financiador competitivo)

Código: EFA281/16/IMLINFO

Duración: 01/01/2018 - 31/12/2020
Dianes terapèutiques i noves tècniques diagnostiques en neoplasies linfoides.

Investigador/a principal: Dolors Colomer Pujol

Financiador: AGAUR (Programa financiador competitivo)

Código: 2017_SGR_1009

Duración: 01/01/2018 - 31/12/2019
neoplasias hematologicas- patologia linfoide

Investigador/a principal: Dolors Colomer Pujol

Financiador: CIBER de enfermedades oncologicas (CIBERONC) (Programa financiador competitivo)

Código: CB16/12/00334.

Duración: 01/01/2017

Dolors Colomer

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

Transpyrenean network of advanced therapies in non-Hodgkin lymphoma - THERAVLINFO (INTERREG-POCTEFA program EFA123/1)

Nuevos modelos para el estudio de las alteraciones genéticas recurrentes y resistencia a fármacos en la leucemia linfática crónica

Cross border network of personalized immunotherapies in non-Hodgkin lymphoma.

Dianes terapèutiques i noves tècniques diagnostiques en neoplasies linfoides.

neoplasias hematologicas- patologia linfoide

Suscríbete a la Newsletter del Clínic